Literature DB >> 28447208

Squamous cell carcinoma of the lung associated with anti-Jo1 antisynthetase syndrome: a case report and review of the literature.

G Boleto1, J-M Perotin2, J-P Eschard3, J-H Salmon3,4.   

Abstract

Antisynthetase syndrome is a heterogeneous idiopathic inflammatory myopathy. Anti-Jo1 is the most common antibody found in this condition. Dermatomyositis is known to be associated with malignancy, but the association between antisynthetase syndrome and malignancy is not clearly established. We report a case of an association of squamous cell carcinoma of the lung and anti-Jo1 antisynthetase syndrome. A 67-year-old man presented with polyarthritis, muscle weakness of the pelvic girdle, "mechanic's hands," and weight loss. A diagnosis of antisynthetase syndrome was considered based on the clinical features and the presence of anti-Jo1 antibodies. Positron emission tomography was performed because of weight loss and revealed a pulmonary hypermetabolic lesion. Histological findings revealed squamous cell carcinoma. The patient underwent lobectomy and is currently free of symptoms with regular monitoring. This unusual presentation of squamous cell carcinoma of the lung illustrates the need of a systematic approach to the diagnosis of antisynthetase syndrome. Positron emission tomography can be a useful imaging modality in the diagnosis of paraneoplastic syndromes associated with antisynthetase syndrome especially in the presence of warning signs/symptoms.

Entities:  

Keywords:  Anti-Jo1 antibodies; Antisynthetase syndrome; Malignancy; Positron emission tomography

Mesh:

Substances:

Year:  2017        PMID: 28447208     DOI: 10.1007/s00296-017-3728-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  26 in total

1.  Antisynthetase syndrome and malignancy: our experience.

Authors:  Marta Castañeda-Pomeda; Sergio Prieto-González; Josep Maria Grau
Journal:  J Clin Rheumatol       Date:  2011-12       Impact factor: 3.517

Review 2.  Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.

Authors:  I Marie; S Josse; O Decaux; S Dominique; E Diot; C Landron; P Roblot; S Jouneau; P Y Hatron; K P Tiev; O Vittecoq; D Noel; L Mouthon; J-F Menard; F Jouen
Journal:  Autoimmun Rev       Date:  2012-02-03       Impact factor: 9.754

3.  A 58-year-old man with anti-Jo-1 syndrome and renal cell carcinoma: a case report and discussion.

Authors:  Guada Respicio; Wassim Shwaiki; Micha Abeles
Journal:  Conn Med       Date:  2007-03

4.  In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease.

Authors:  R La Corte; A Lo Mo Naco; A Locaputo; F Dolzani; F Trotta
Journal:  Autoimmunity       Date:  2006-05       Impact factor: 2.815

5.  Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience.

Authors:  Linda M Mileti; Mary E Strek; Timothy B Niewold; James J Curran; Nadera J Sweiss
Journal:  J Clin Rheumatol       Date:  2009-08       Impact factor: 3.517

6.  A case report of a patient with dermatomyositis as a prodromal sign of lung cancer.

Authors:  Grzegorz Przybylski; Agnieszka Jarzemska; Jarosław Czerniak; Krystyna Siemiatkowska; Aleksandra Gadzińska; Krzysztof Cieśliński
Journal:  Pol Arch Med Wewn       Date:  2008-03

7.  [A case of interstitial pneumonitis associated with polymyositis complicated by renal cell carcinoma].

Authors:  Y Iwasaki; T Mohri; M Muraki; A Yasukawa; T Fujimoto; O Takagi; Y Tsuya; S Nakajima
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1992-10

8.  Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study.

Authors:  H Chinoy; S Adimulam; F Marriage; P New; M Vincze; E Zilahi; A Kapitány; A Gyetvai; L Ekholm; P Novota; M Remakova; P Charles; N J McHugh; L Padyukov; L Alfredsson; J Vencovsky; I E Lundberg; K Danko; W E Ollier; R G Cooper
Journal:  Ann Rheum Dis       Date:  2011-12-20       Impact factor: 19.103

Review 9.  Malignancy in patients with inflammatory myopathy.

Authors:  Rachelle Buchbinder; Catherine L Hill
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.686

10.  Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome.

Authors:  Isabelle Marie; Pierre-Yves Hatron; Patrick Cherin; Eric Hachulla; Elisabeth Diot; Olivier Vittecoq; Jean-François Menard; Fabienne Jouen; Stéphane Dominique
Journal:  Arthritis Res Ther       Date:  2013-10-08       Impact factor: 5.156

View more
  4 in total

Review 1.  Antisynthetase syndrome: A distinct disease spectrum.

Authors:  Kun Huang; Rohit Aggarwal
Journal:  J Scleroderma Relat Disord       Date:  2020-02-18

Review 2.  Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond.

Authors:  Angeles S Galindo-Feria; Antonella Notarnicola; Ingrid E Lundberg; Begum Horuluoglu
Journal:  Front Immunol       Date:  2022-05-13       Impact factor: 8.786

3.  Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report.

Authors:  Andrew J Beel; David S Demos; Alfred Chung; Charles Liao; Natalie S Lui
Journal:  J Cardiothorac Surg       Date:  2018-02-07       Impact factor: 1.637

4.  EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib.

Authors:  Reina Hara; Masaki Kanazu; Ami Iwai; Tomoki Kuge; Mikako Ishijima; Takeshi Uenami; Yuki Akazawa; Yukihiro Yano; Toshihiko Yamaguchi; Masahide Mori
Journal:  Thorac Cancer       Date:  2021-03-07       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.